Transgene

Transgene S.A.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
62.08 M
Public Float
-
Transgene S.A.
Stock Exchange Euronext Paris
EPS
EUR0.13
Market Cap
EUR202.98 M
Shares Outstanding
83.27 M
Public Float
23.75 M

Profile

Address
400 Boulevard Gonthier dAndernach
Strasbourg Alsace 67405
France
Employees -
Website http://www.transgene.fr
Updated 07/08/2019
Transgene SA is a biotechnology company, which engages in the research, development, and manufacture of immunotherapies for the treatment of cancer and infectious diseases. Its products include TG4010, Pexa-Vec, TG4001, TG6002, TG1050, and TG4040. The company was founded in December 1979 and is headquartered in Strasbourg, France.

Financials

View All
Created with Highcharts 5.0.14Transgene S.A.Net Income. Fiscal year is January-December. All values EUR Thousands.42 85842 85841 11641 11637 90937 90924 18324 18332 27432 2748 0268 026201320142015201620172018010k20k30k40k50k
Created with Highcharts 5.0.14Transgene S.A.Sales/Revenue. Fiscal year is January-December. All values EUR Thousands.3 8493 8491 8371 8371 4651 4652 3462 3462 0992 0991 3351 33520132014201520162017201801k2k3k4k5k

Philippe Archinard
Chairman & Chief Executive Officer
Alain Mérieux
Director